High Inflammatory Factor Grading Predicts Poor Disease-Free Survival in AJCC Stage I-II Hepatocellular Carcinoma Patients After R0 Resection

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2 ):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6 ):394–424. doi:10.3322/caac.v68.630207593
   PubMed Web of Science ®Google Scholar
• Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2 ):181–200. doi:10.1055/s-2005-87119815918147
   PubMed Web of Science ®Google Scholar
• Tu T, Budzinska MA, Maczurek AE, et al. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15(6 ):9422–9458. doi:10.3390/ijms1506942224871369
   PubMed Web of Science ®Google Scholar
• Giannelli G, Rani B, Dituri F, et al. Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut. 2014;63(10 ):1668–1676. doi:10.1136/gutjnl-2014-30732325053718
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144(3 ):512–527. doi:10.1053/j.gastro.2013.01.00223313965
   PubMed Web of Science ®Google Scholar
• Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117(5 ):1175–1183. doi:10.1172/JCI3153717476347
   PubMed Web of Science ®Google Scholar
• Jeng KS, Chang CF, Jeng WJ, et al. Heterogeneity of hepatocellular carcinoma contributes to cancer progression. Crit Rev Oncol Hematol. 2015;94(3 ):337–347. doi:10.1016/j.critrevonc.2015.01.00925680939
   PubMed Web of Science ®Google Scholar
• Villa E, Critelli R, Lei B, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a Prospective Study. Gut. 2016;65(5 ):861–869.25666192
   PubMedGoogle Scholar
• Kamarajah SK, Frankel TL, Sonnenday C, et al. Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): a Surveillance, Epidemiology, End Results (SEER) analysis. J Surg Oncol. 2018;117(4 ):644–650. doi:10.1002/jso.2490829127719
   PubMed Web of Science ®Google Scholar
• Kamiyama T, Orimo T, Wakayama K, et al. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification. World J Surg Oncol. 2017;15(1 ):156. doi:10.1186/s12957-017-1229-x28830473
   PubMedGoogle Scholar
• Attallah AM, Omran MM, Attallah AA, et al. Simplified HCC-ART score for highly sensitive detection of small-sized and early-stage hepatocellular carcinoma in the widely used Okuda, CLIP, and BCLC staging systems. Int J Clin Oncol. 2017;22(2 ):332–339. doi:10.1007/s10147-016-1066-x27864623
   PubMed Web of Science ®Google Scholar
• Liu C, Duan LG, Lu WS, et al. Prognosis evaluation in patients with hepatocellular carcinoma after hepatectomy: comparison of BCLC, TNM and Hangzhou criteria staging systems. PLoS One. 2014;9(8 ):e103228. doi:10.1371/journal.pone.010322825133493
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66(2 ):338–346. doi:10.1016/j.jhep.2016.09.00827677714
   PubMed Web of Science ®Google Scholar
• Jang JW, Oh BS, Kwon JH, et al. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012;60(3 ):686–693. doi:10.1016/j.cyto.2012.07.01722906998
   PubMed Web of Science ®Google Scholar
• Ohishi W, Cologne JB, Fujiwara S, et al. Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study. Int j Cancer. 2014;134(1 ):154–163. doi:10.1002/ijc.v134.123784949
   PubMed Web of Science ®Google Scholar
• Soresi M, Giannitrapani L, D’Antona F, et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World j Gastroenterol. 2006;12(16 ):2563–2568. doi:10.3748/wjg.v12.i16.256316688802
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Urbanska-Rys H, Robak T. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma. Br J Haematol. 1999;105(2 ):412–419. doi:10.1111/bjh.1999.105.issue-210233412
   PubMed Web of Science ®Google Scholar
• Okamoto K, Ishida C, Ikebuchi Y, et al. The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern Med. 2010;49(10 ):887–895. doi:10.2169/internalmedicine.49.326820467172
   PubMed Web of Science ®Google Scholar
• Jiang R, Xia Y, Li J, et al. High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer. Int j Cancer. 2010;126(5 ):1263–1274. doi:10.1002/ijc.2485419728335
   PubMed Web of Science ®Google Scholar
• He G, Yu GY, Temkin V, et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 2010;17(3 ):286–297. doi:10.1016/j.ccr.2009.12.04820227042
   PubMed Web of Science ®Google Scholar
• Yokota T, Wang Y. p38 MAP kinases in the heart. Gene. 2016;575(2 Pt 2 ):369–376. doi:10.1016/j.gene.2015.09.03026390817
   PubMed Web of Science ®Google Scholar
• Sathish Kumar P, Viswanathan MBG, Venkatesan M, Balakrishna K. Bauerenol, a triterpenoid from Indian Suregada angustifolia: induces reactive oxygen species-mediated P38MAPK activation and apoptosis in human hepatocellular carcinoma (HepG2) cells. Tumour Biol. 2017;39(4 ):1010428317698387. doi:10.1177/101042831769838728443465
   PubMedGoogle Scholar
• Bai ZT, Wu ZR, Xi LL, et al. Inhibition of invasion by N-trans-feruloyloctopamine via AKT, p38MAPK and EMT related signals in hepatocellular carcinoma cells. Bioorg Med Chem Lett. 2017;27(4 ):989–993. doi:10.1016/j.bmcl.2016.12.07328073674
   PubMed Web of Science ®Google Scholar
• Lin JJ, Su JH, Tsai CC, et al. 11-epi-Sinulariolide acetate reduces cell migration and invasion of human hepatocellular carcinoma by reducing the activation of ERK1/2, p38MAPK and FAK/PI3K/AKT/mTOR signaling pathways. Mar Drugs. 2014;12(9 ):4783–4798. doi:10.3390/md1209478325222667
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Di Fazio I, Laurino A, et al. Role of interleukin 6 in hepatocellular carcinoma. Bull Cancer. 1996;83(5 ):379–384.8680090
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang S, Yang Z, et al. Association between the expression levels of IL-6 and IL-6R in the hepatocellular carcinoma microenvironment and postoperative recurrence. Oncol Lett. 2018;16(6 ):7158–7165. doi:10.3892/ol.2018.955730546452
   PubMed Web of Science ®Google Scholar
• Amano H, Tashiro H, Oshita A, et al. Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria. J Gastrointest Surg. 2011;15(7 ):1173–1181. doi:10.1007/s11605-011-1538-221512850
   PubMed Web of Science ®Google Scholar
• Kaneko K, Shirai Y, Wakai T, et al. Low preoperative platelet counts predict a high mortality after partial hepatectomy in patients with hepatocellular carcinoma. World j Gastroenterol. 2005;11(37 ):5888–5892. doi:10.3748/wjg.v11.i37.588816270404
   PubMed Web of Science ®Google Scholar
• Löhe F, Angele MK, Rentsch M, et al. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant. 2007;21(6 ):696–701. doi:10.1111/j.1399-0012.2007.00707.x17988261
   PubMed Web of Science ®Google Scholar
• Hubert C, Sempoux C, Rahier J, et al. Prognostic risk factors of survival after resection of hepatocellular carcinoma. Hepato-Gastroenterology. 2007;54(78 ):1791–1797.18019720
   PubMedGoogle Scholar